Navigation Links
Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
Date:6/10/2008

CALGARY, June 10 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP) administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The National Cancer Institute (NCI), part of the National Institutes of Health, is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R). The Principal Investigator is Dr. David E. Cohn, Associate Professor, Division of Gynecologic Oncology at The Ohio State University College of Medicine in Columbus, Ohio.

"REOLYSIN(R) is an exciting agent to investigate in patients with ovarian cancer," said Dr. Cohn. "Targeting a specific alteration commonly present in these tumors will hopefully lead to efficacy with minimal toxicity."

"We are looking forward to working closely with the NCI to examine the effects of using REOLYSIN(R) with two concurrent methods of administration," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our REOLYSIN(R) clinical program has now expanded to include ten Phase 1/2 or Phase 2 trials in the U.S. and the U.K. using REOLYSIN(R) as a monotherapy or in combination with radiation or chemotherapy."

In the Phase 1 portion of the trial, patients will receive a constant dose of IV REOLYSIN(R) on days 1-5 every 28 days, as well as an escalating dose of IP REOLYSIN(R) on days 1-2 every 28 days. In the Phase 2 portion of the study, patients will receive a constant dose of IV REOLYSIN(R) on days 1-5 every 28 days as well as the Maximum Tolerated Dose (MTD) of IP REOLYSIN(R) from the Phase 1 portion.

The primary objectives of the Phase 1 trial are to determine the safety and tolerability of intravenous and intraperitoneal adminis
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
4. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
5. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
6. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
7. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
8. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
11. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ("Aptose" ... three months ended March 31, 2015 and provided a ... Canadian dollars. Effective July 17, 2014 ... 31 to December 31. As a result of that ... the three months ended March 31, 2015, while the ...
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... 2015 Psyche Systems Corporation and Luminate Health ... first-of-its-kind platform that helps labs comply with new federal ... the way patients engage with these results, and improves ... provides a HIPAA-compliant digital platform that gives labs an ... their lab results, and uniquely connects labs, physicians, and ...
(Date:5/5/2015)... 2015  Renova™ Therapeutics, a biopharmaceutical company developing ... other chronic diseases, has engaged RAND Health Advisory ... reflect the healthcare patterns of multiple advanced heart ... used to characterize the impact the company,s lead ... groups of patients and the overall health care ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... ... ensure future crisis prevented. , ... Davos-Klosters, Switzerland (Vocus) Jan. 29, 2010 -- Agriculture is a game-changer that ... such as civil unrest, DuPont Chair and CEO Ellen Kullman told attendees ...
... , Data Demonstrating a 35% Overall Response ... in Patients with Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to ... Issue of the Journal of Clinical Cancer Research , ... Zentaris Inc. (Nasdaq: AEZS ; TSX: AEZ) (the ...
... , Jan. 28 RSB Spine, LLC, today ... the company,s 510(k) application to permit the marketing of its ... Executive Officer John A. Redmond said: "We are ... distributors two additional products to offer customers seeking greater options ...
Cached Biology Technology:DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... across the United States and Russia are departing July 2 ... program, known as The Polaris Project, is training future leaders ... the impacts of climate change. Dr. R. ... Center and director of the Polaris Project, says, "The Arctic ...
... researchers have been able to identify genetic predictors of the ... Cathy Allen, from the Rotunda Hospital, Dublin, Ireland, told the ... and Embryology today (Wednesday 1 July) that her research would ... for others. Previous work in this area has looked ...
... of forest biotechnology to help address significant social and ... rigid opposition of some groups and regulations that effectively ... argue in a new report. Steps must be ... modified trees on a scientific, case-by-case basis, and is ...
Cached Biology News:International team of students and scientists on month-long field course in Siberian Arctic 2International team of students and scientists on month-long field course in Siberian Arctic 3Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3Anti-biotech groups obstruct forest biotechnology 2Anti-biotech groups obstruct forest biotechnology 3
Mouse Activin RIB/ALK-4 MAb (Clone 207304)...
geminin, DNA replication inhibitor...
Complement C1r [Human]...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: